Highly active antiretroviral therapy (HAART), while clearly invaluable, does not halt growth or proliferation of HL, in fact, while AIDS-defining malignancies like Kaposi’s sarcoma (KS) and non-Hodgkin’s lymphoma (NHL) have declined thanks to HAART, the incidence of HL in HIV patients has actually increased, from 14 times higher than that of non-HIV patients in the pre-HAART era to 32 times higher in the HAART era. Typical ...more »
How can the effectiveness of existing curative therapies be improved for allogeneic hematopoietic stem cell transplantation?
How can the use of CAR T-cell and checkpoint blockade strategies be optimized in order to cure hematologic diseases?
As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan: What role should sublingual immunotherapy play in the treatment of asthma?
CAR therapy has resurrected the role of immunotherapy in treating cancer. But it has significant toxicity. Can we train , standardize the care of and adequately oversee the care of patients getting CAR therapy , especially as company begin to approach FDA for approval of this therapy and up scale for mass treatment.